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A B S T R A C T
Cesarean delivery occurs in roughly one third of pregnancies. Effective postoperative pain control is a goal
for patients and physicians. Limiting opioid use in this period is important as some percentage of opioid
naïve individuals will develop persistent use. Gabapentin is a non-opioid medication that has been used
perioperatively to improve postoperative pain and limit opioid requirements. The goal of this study is to
determine the efﬁcacy of perioperative gabapentin in improving post cesarean delivery pain control. The
following data sources were searched from their inception through October 2018: MEDLINE, Ovid,
ClinicalTrials.gov, Sciencedirect, and the Cochrane Library at the CENTRAL Register of Controlled Trials. A
systematic review of the literature was performed to include all randomized trials examining the effect of
perioperative gabapentin on post cesarean delivery pain control and other postoperative outcomes. The
primary outcome was analgesic effect of gabapentin on post cesarean delivery pain, measured by visual
analog scale (VAS; 0–100) or Numerical Rating Scale (NRS; 0–10) on movement 24 h postoperative. These
scores were directly compared by multiplying all NRS scores by a factor of 10. Meta-analysis was
performed using the random effects model of DerSimonian and Laird, to produce summary treatment
effects in terms of mean difference (MD) with 95% conﬁdence interval (CI). Six placebo controlled trials
(n = 645) were identiﬁed as relevant and included in the meta-analysis. All studies included only healthy
pregnant women (American Society of Anesthesiologist (ASA) physical status I or II) undergoing spinal
anesthesia for cesarean delivery at term. Participants were randomized to either 600 mg oral gabapentin
or placebo preoperatively and in one study the medications were also continued postoperatively. Pooled
data showed that women who received gabapentin prior to cesarean delivery had signiﬁcantly lower VAS
pain scores at 24 h after movement (MD -11.58, 95% CI -23.04 to -0.12). VAS pain scores at other time
intervals at rest or after movement were not signiﬁcantly different for those who received gabapentin
and placebo although there was a general trend toward lower pain scores for women receiving
gabapentin. There was no signiﬁcant between-group difference in use of additional pain medications,
supplemental opioids, and maternal or neonatal side effects. There was higher pain control satisfaction at
12 and 24 h in the gabapentin versus placebo groups.
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Cesarean delivery occurs in approximately 32%, of pregnancies
and is one of the most commonly performed surgical procedures in
the United States among reproductive aged women [1]. It involves a
large abdominal incision, so post-operative pain control is a concern
for patients and their families. Poor pain control in the postpartum
period has been shown to contribute to postpartum depression and
to be a risk factor for developing chronic pain syndromes [2–5].
Regional anesthesia for cesarean delivery typically consists of
intrathecal injection of local anesthetic and a lipophilic opioid. The
addition of intrathecal morphine has been shown to provide
analgesia in the postoperative period for 14–36 h and to reduce
postoperative opioid requirements [5]. Regimens for postoperative
pain control typically include combinations of acetaminophen,
nonsteroidal anti-inﬂammatory drugs (NSAIDs) and systemic
opioid medications. These may be administered intravenously,
intramuscularly, orally, or rectally [3,5].
In addition to optimal postoperative pain control, limiting
opioid use is a further goal for healthcare providers as a percentage
of opioid naive women will exhibit persistent use postoperatively
[6]. As the number of individuals with opioid use disorder
continues to rise, alternative analgesic options and strategies to
limit opioid consumption become increasingly important.
Gabapentin is an anticonvulsant medication approved by the
Federal Drug Administration (FDA) for epilepsy treatment as well
as neuropathic pain conditions. It works in part by decreasing
excitatory neurotransmitter action in the nervous system to
dampen afferent nocioceptive signaling. It has also been used
perioperatively for a variety of surgeries to decrease postoperative
pain and opioid consumption with varying efﬁcacy. A meta-
analysis by Alayed et al. showed reduced postoperative pain scores
as well as decreased opioid requirements in the ﬁrst 24 h following
hysterectomy when used perioperatively [7]. Gabapentin is
generally considered safe for use in pregnancy, with only rare
reports of neonatal withdrawal associated with prolonged use [8].
The aim of this systematic review and meta-analysis was to
determine the efﬁcacy of perioperative gabapentin in improving
postoperative pain control in healthy women undergoing cesarean
delivery at term under spinal anesthesia.
Material and methods
Sources
This review was performed according to a protocol designed a
priori and recommended for systematic review [9]. Electronicdatabases (MEDLINE, Ovid, ClinicalTrials.gov, Sciencedirect, the
Cochrane Library at the CENTRAL Register of Controlled Trials)
were searched from their inception until October 2018. Search
terms used were the following text words: “cesarean,” “caesarean,”
“postoperative,” “analgesia,” “pain” and “gabapentin.” No
Fig. 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial; Plus sign: low risk of bias; minus sign: high risk of bias; question mark: unclear risk of bias. (B) Risk
of bias graph about each risk of bias item presented as percentages across all included studies.
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addition, the reference lists of all identiﬁed articles were examined
to identify studies not captured by electronic searches. The
electronic search and the eligibility of the studies were indepen-
dently assessed by two authors (LF, GS). Differences were discussed
and consensus reached.
Study selection
This study included all randomized controlled trials examining
the effect of perioperative gabapentin on post cesarean delivery
analgesia and other postoperative outcomes including nausea,
vomiting, and pain related to spinal headache. Eligible studies
included trials comparing patients receiving at least one dose of
gabapentin with a control group (either placebo or no treatment).We included only studies in which women with singleton
gestations received spinal anesthesia and underwent cesarean
delivery at term (37weeks). Trials including multiple gestations,
pretermdelivery,generalanesthesia,studiescomparinggabapentinto
another drug, and quasi-randomized trials (i.e. trials in which
allocation was done on the basis of a pseudo-random sequence, e.g.
odd/even hospital numberordateof birth, alternation)wereexcluded.
Risk of bias
The risk of bias in each included study was assessed using the
criteria outlined in the Cochrane Handbook for Systematic Reviews of
Interventions. Seven domains related to risk of bias were assessed
in each included trial since there is evidence that these issues are
associated with biased estimates of treatment effect: 1) random
Table 1
Characteristics of the included trials.
Study location Sample size* Inclusion criteria Exclusion criteria Primary outcome
Moore et al. [11] Canada 44
(21 vs 23)
 Term
 Scheduled cesarean
 Age 18
 HIV
 Hepatitis
 Uncontrolled HTN or DM
 IV drug user
 Fetal congenital abnormalities
 Use of pain medication in the past
week
VAS pain on movement at
24 hrs postop
Short et al. [12] Canada 88
(44 vs 44)
 Term
 Scheduled cesarean
 Singleton
 Epilepsy
 CNS or mental disorders
 Chronic pain
 Drug abuse
 Use of neuropathic analgesic or
antiepileptic drugs
 Fetal congenital abnormalities
VAS pain on movement at
24 hours postop
Nofal et al. [13] Egypt 86
(42 vs 44)
 Term
 Scheduled cesarean
 Singleton
 Primiparous
 Multiparous
 Chronic headaches
 Chronic pain
 Regular analgesics or antiepileptic
medication use
 Fetal congenital abnormalities
Not reported Post-dural
puncture headache
characteristics
Memari et al. [14] Iran 200
(100 vs 100)
 Hemoglobin > 10 g/dl
 Fasting 6-8 hours prior to
surgery
 Cardiovascular disease
 GI disease
 Middle ear disease
 Vertigo
 Motion sickness
 DM
 HTN
 Smoking or alcohol consumption
 Nausea/ vomiting before surgery
 Fever/ infection
 Received additional postoperative
medications within 6 hrs (only anti-
biotics and sedatives)
VAS score for nausea and
vomiting postop
Monks et al. [15] Canada 197
(100 vs 97)
 Term
 Scheduled cesarean
 Ages 18-55
 Epilepsy
 Chronic pain
 Use of anticonvulsants or neuro-
pathic analgesics
 Opioid or IV drug abuser
 Use of antacid in previous 3 hours
VAS pain on movement at
24 h postop
Hafez et al. [16] Egypt 45
(15 vs 15)
 Term
 Scheduled cesarean
 20-40 yrs old
 Uncomplicated pregnancy
 Epilepsy
 Routine use of antiepileptic medi-
cations
 Kidney or liver impairment
 Alcoholism/ IV drug use
 HTN
 Oligohydramnios/ polyhydramnios
 Antepartum hemorrhage
 Psychiatric disorder
 Inability to communicate
NRS pain score
HIV: human immunodeﬁciency virus; HTN: hypertension; DM: diabetes mellitus; CNS: central nervous system; GI: gastrointestinal.
* Data are reported as total number (number in the intervention vs number in the control group).
Table 2
Characteristics of the included women.
Maternal age Gestational age at randomization BMI (kg/m2)
Moore et al. [11] 35  5 vs 34  6 38.8  0.7 vs 38.9  0.8 29  4 vs 30  6
Short et al. [12] 34.8  4.1 vs 35.3  4.8 38.7 vs 38.5* 30.6  5.6 vs 29.3  4.3
Nofal et al. [13] 32.1  4.8 vs 30.7  5.2 Not reported Not reported
Memari et al. [14] 26.1  5.2 vs 26.1  5.2 38.2  0.5 vs 38.1  0.4 Not reported
Monks et al. [15] 35.9  3.9 vs 34.7  4.5 38.7  0.8 vs 38.6  0.9 30.8  5.1 vs 31.2  5.6
Hafez et al. [16] 28.2  4.7 vs 27.3  5.5 38.3  1.1 vs 38.1  1.0 Not reported
Data are reported as mean  standard deviation.
* Median.
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Table 3
Preoperative and intraoperative pain management.
Intervention
group
Control
group
Timing of
intervention
Anesthesia intraoperative medications received by both
intervention and control groups
Additional intraoperative meds
as needed
Moore et al. [11] 600 mg oral
gabapentin
Lactose
placebo
1 hr prior to
surgery
Intrathecal: 0.75% hyperbaric bupivacaine 12 mg, Fentanyl
10 mg, Morphine100 mg
Up to 100 mg IV fentanyl as
needed
Short et al. [12] 600 mg oral
gabapentin
Lactose
placebo
1 hr prior to
surgery
Intrathecal: 13.5 mg 0.75% hyperbaric bupivacaine, 10 mg
fentanyl, 100 mg morphine
IV fentanyl at discretion of
anesthesiologist
Nofal et al. [13] 600 mg oral
gabapentin
Starch
placebo
2 hrs prior to
surgery
Intrathecal: 12.5 mg hyperbaric bupivacaine 0.5%, 25 mg
fentanyl
None
Memari et al. [14] 600 mg oral
gabapentin
Placebo 1 hr prior to
surgery
Spinal Not reported
Monks et al. [15] 600 mg oral
gabapentin
Placebo 1 hr prior to
surgery
Intrathecal: 1.6-1.8 ml 0.75% hyperbaric bupivacaine, 10 mg
fentanyl, 100 mg morphine
Up to 100 mg fentanyl IV
Hafez et al. [16] 600 mg oral
gabapentin
Placebo 1 hr prior to
surgery
Intrathecal: 8 mg bupivacaine, 25 mg fentanyl None
Hr: hour; IV: intravenous.
Table 4
Intraoperative characteristics.
Skin incision Repeated cesarean Duration of surgery (minutes)
Moore et al. [11] Not reported 18/21 (85.7%) vs 15/23 (65.2%) Not reported
Short et al. [12] Pfannenstiel 30/42 (71.4%) vs 33/42 (78.6%) Not reported
Nofal et al. [13] Not reported 26/42 (61.9%) vs 24/44 (54.5%) 55.7  6.9 vs 57.8  7.3
Memari et al. [14] Not reported Not reported Not reported
Monks et al. [15] Pfannenstiel 76/100 (76.0%) vs 70/97 (72.2%) Not reported
Hafez et al. [16] Not reported Not reported Not reported
Data are reported as mean  standard deviation or as number percentage (number in the intervention vs number in the control group).
Table 5
Immediate postoperative medications used in both groups.
NSAID –
immediately
postop
Acetaminophen-
immediately
postop
Postoperative pain meds –
standing
Postoperative pain meds – as needed Anti-emetics, anti-itch
Moore et al. [11] Ketorolac
30mg IV
Acetaminophen
1g per rectum
 Diclofenac 50mg q8h po
 Acetaminophen 1 g po q6h for
72 hrs
 PACU: Morphine 2 mg IV q5 mins prn
 Ward: Morphine 2mg subcutaneous
q4hrs in ﬁrst 24 hrs, then 5 mg po q4
hrs
 Dimenhydrinate 50 IM q6h
 Diphenhydramine 25 IM q4h
Short et al. [12] Ketorolac 30
mg IV
Acetaminophen
1300mg per
rectum
 Diclofenac 50mg q8h po
 Acetaminophen 1 g q6h po x 72
hrs
 First 24 hrs: Morphine 2 mg subcu-
taneous prn
 After: Morphine 10 mg po
 Dimenhydrinate 50 mg IM q6h
prn
 Nalbuphine 5 mg subcutaneous
q4h prn
Nofal et al. [13] Not reported Not reported  Diclofenac 50mg IM alternat-
ing with IV Acetaminophen q
12 hours
 Meperidine 50 mg IM prn All received antacids
Memari et al. [14] Not reported Not reported Not reported Not reported Not reported
Monks et al. [15] Ketorolac 30
mg IV
Acetaminophen
1300 mg per
rectum
 Diclofenac 50mg q8h
 Acetaminophen 1g po q6h
 Gabapentin 200mg or placebo
q8 x 48 hrs
 PACU: Morphine 2mg IVq5mins
 Floor:
 First 24h: Morphine subcutaneous or
IV 2mg or Hydromorphone 0.4mg
q1h
 After 24h: Morphine 10mg po or
Hydromorphone 2 mg
 Zofran
 Metoclopramide
 Dimenhydrinate
Hafez et al. [16] Not reported Not reported Not Reported  Meperidine IV 1 mg/kg IM in ﬁrst 24
hrs
 Zofran
 Ranitidine
IV: intravenous; po: per os (oral); IM: intramuscular; q: every; h: hours; prn: pro re nata (as needed).
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participants and personnel; 4) blinding of outcome assessment; 5)
incomplete outcome data; 6) selective reporting; and 7) other bias.
Review authors’ judgments were categorized as “low risk”, “high
risk” or “unclear risk” of bias [9].Two authors (LF, GS) independently assessed inclusion criteria,
risk of bias and data extraction. Disagreements were resolved by
discussion.
All analyses were done using an intention-to-treat approach,
evaluating women according to the treatment group to which they
Fig. 3. Forest plot for the risk of VAS pain scores at postoperative on movement.
Table 6
VAS Pain scores outcomes.
VAS 6 h
movement
(mm)
VAS 6 h rest
(mm)
VAS 12h
Movement
(mm)
VAS 12h
Rest (mm)
VAS 24 h
movement
(mm)
VAS 24 h
rest (mm)
VAS 48 h
movement (mm)
VAS 48 h rest
(mm)
Moore et al. [11] Not Reported Not Reported 19.95  16.87
vs
45.00  24.39
11.86  10.36 vs
22.61  20.23
20.95  17.38 vs
41.39  22.08
12.05  13.88 vs
18.70  15.53
17.29  17.96 vs
32.09  21.67
7.9  11.94 vs
14.41  17.91
Short et al. [12] 31.5  23.3 vs
39.5  26.9
15.3  15.1 vs
19.3  20.9
32.7  22.5 vs
38.7  23.6
15.6  14.9 vs
16.7  15.9
37.8  21.8 vs
34.8  23.5
15.3  16.0 vs
14.3  15.6
26.5  19.2 vs
34.3  24.1
13.2  12.8 vs
13.7  16.9
Nofal et al. [13] Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported
Memari et al. [14] Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported
Monks et al. [15] Not Reported Not Reported Not Reported Not Reported 40.0  22.5 vs
46.8  23.1
13.1  16.7 vs
19.1  18.1
34.0  21.5 vs
36.0  24.5
13.0  15.3 vs
16.0  17.0
Hafez et al. [16] 42.0 -8.1
vs 29.0  9.0
Not Reported 30.0  8.0
vs 23.0  16.0
Not Reported 30.0  7.2
vs 52.0  8.2
Not Reported Not Reported Not Reported
Total 36.8 vs 34.3 15.3 vs 19.3 27.5 vs 35.6 13.7 vs 19.7 32.2 vs 43.7 13.5 vs 17.4 25.9 vs 34.1 11.4 vs 14.7
I2 91% N/A 88% 64% 89% 38% 47% 0%
MD (95% CI) 2.99 (17.57 to
23.54)
4.00 (11.80
to 3.80)
7.60 (24.97
to 9.77)
5.32 (14.71 to
4.06)
11.60 (23.03
to -0.16)
3.90 (8.62 to
0.82)
6.90 (13.92 to
0.13)
3.03 (6.45 to
0.38)
Data are reported as mean  standard deviation in the intervention vs control group.
MD, mean difference; CI, conﬁdence interval; N/A, not applicable.
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registered with the PROSPERO International Prospective Register
of Systematic Reviews (Registration Number: CRD42018099832).
Primary and secondary outcomes
The primary outcome was the VAS pain score on movement at
24 h postoperative. Secondary outcomes were VAS pain scores at
other time intervals both at rest or on movement following
surgery, use of additional intraoperative pain medications or
supplemental opioids, pain control satisfaction, persistent pain
after cesarean delivery, maternal side effects, and neonatal
outcomes. Maternal side effects examined include nausea,
vomiting, pruritus, and sedation. Neonatal outcomes evaluated
include APGARs at 1 and 5 min, birth weight, umbilical cord arterial
pH, neonatal intensive care unit admissions, breast feeding
difﬁculties in ﬁrst 24 h, and need for positive pressure ventilation.
Statistical analysis
The data analysis was completed independently by two authors
(LF, GS) using Review Manager v. 5.3 (The Nordic Cochrane Centre,
Cochrane Collaboration, 2014, Copenhagen, Denmark). The com-
pleted analyses were then compared, and any difference was
resolved by discussion with a third reviewer (VB).
Data from each eligible study were extracted without
modiﬁcation of original data onto custom-made data collection
forms. A 2 by 2 table was assessed for relative risk (RR); for
continuous outcomes, means  standard deviation were extracted
and imported into Review Manager v. 5.3.Meta-analysis was performed using the random effects model
of DerSimonian and Laird, to produce summary treatment effects
in terms of either a RR or mean difference (MD) with 95%
conﬁdence interval (CI). Heterogeneity was measured using I-
squared (Higgins I2).
Potential publication biases were assessed statistically using
Begg’s and Egger’s tests. P value <0.05 was considered statistically
signiﬁcant.
The meta-analysis was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) statement [10].
Results
Study selection and study characteristics
The ﬂow of study identiﬁcation is shown in Fig. 1. Six trials were
identiﬁed as relevant, included in the meta-analysis and analyzed
[11–16]. Publication bias, assessed statistically using Begg’s and
Egger’s test, showed no signiﬁcant bias (P = 0.57 and P = 0.52,
respectively). Statistical heterogeneity within the trials ranged
from low to moderate with no inconsistency (I2 = 0%) for several of
the secondary outcomes, and I2 = 89% for the primary outcome.
The quality of the RCTs included in our meta-analysis was
assessed using the seven criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions. Most of the
included studies were judged as “low risk” of bias in most of the
seven Cochrane domains related to the risk of bias. All the included
studies had “low risk” of bias in “random sequence generation.” All
the trials were placebo-controlled studies, and neither the
Table 7
Secondary outcomes.
Women requiring additional
intraoperative pain
medications
Average mg of IV morphine
equivalents used as needed in 24hours
for patients requiring additional
analgesia
Women requiring
supplemental narcotics in
ﬁrst 24hrs
Pain control
satisfaction 6hrs
(mm)
Pain control
satisfaction 12hrs
(mm)
Pain control
satisfaction 24hrs
(mm)
Pain control
satisfaction 48 hrs
(mm)
Persistent pain 6
weeks after delivery
Moore et al. [11] 0/21 vs 1/23 (4.3%) 4.22.5 vs 3.21.8 5/21 (23.8%) vs 5/23 (21.7%) Not reported 94.88.1 vs
79.120.0
90. 15.5
vs 77.817.8
92.911.0
vs 87.312.4
2/16 (12.5%) vs
4/20 (20.0%)
Short et al. [12] 1/42 (2.4%) vs 3/42 (7.1%) 6.73.6 vs 7.93.8 14/42 (33.3%) vs 16/42
(30.1%)
84.020.0 vs
82.021.0
84.717.7 vs
78.222.6
85.315.1
vs 80.521.6
81.024.0
vs 83.818.5
6/42 (14.3%) vs
1/42 (2.4%)
Nofal et al. [13] 0/42 vs 0/44 Not reported Not reported Not reported Not reported Not reported Not reported Not reported
Memari et al. [14] Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported
Monks et al. [15] 1/100 (1.0%) vs 3/97 (3.1%) 8.75.2 vs 9.16.7 23/100 (23) vs 31/97 (32) Not reported Not reported 86.517.5
vs 7722.9
85.519.3
vs 81.321.4
4/71(5.6%) vs 3/71
(4.2%)
Hafez et al. [16] 0/15 vs 0/15 Not reported 15/15 (100%) vs 15/15
(100%)
Not reported Not reported Not reported Not reported Not reported
Total 2/205 (1.0%) vs 7/206 (3.4%) 6.5 vs 6.7 57/178 (32.0%) vs 67/177
(37.9%)
84.0 vs 82.0 89.8 vs 78.7 87.3 vs 78.4 – 12/129 (9.3%) vs 8/
133 (6.0%)
I [2] 0% 58% 60% Not applicable 54% 0% 13% 34%
RR or MD (95% CI) 0.32 (0.08 to 1.38) 0.14 (-1.48 to 1.20) 0.90 (0.62 to 1.29) 2.00 (6.57 to
10.57)
11.00 (1.99 to
20.02)
8.64 (4.47 to
12.81)
3.20 (1.09 to
7.48)
1.47 (0.45 to 4.79)
Data are reported as mean standard deviation or as number (percentage) in the intervention vs control group. Boldface data, statistically signiﬁcant.
MD, mean difference; CI, conﬁdence interval; RR, relative risk.
Table 8
Maternal Side effects within 48 h.
Nausea Vomiting Pruritus Sedation
Moore et al. [11] 12/21 (57.1%) vs 8/23 (34.8%) 5/21 (23.8%) vs 3/23 (13.0%) 16/21 (76.2%) vs 22/23
(95.7%)
17/21 (80.9%) vs 17/23 (73.9)
Short et al. [12] 19/42 (45.2%) vs 19/42 (45.2%) 7/42 (16.7%) vs 10/42 (23.8%) 33/42 (78.6%) vs 32/42 (80.9%) 23/42 (54.8%) vs 24/42 (57.1%)
Nofal et al. [13] 7/42 (16.6%) vs
9/44 (20.5%)
Not reported Not reported 11/42 (26.2%) vs 3/44 (6.8%)
Memari et al. [14] 27/100 (27.0%) vs 41/100 (41.0%) 25/100 (25.0%) vs 38/100 (38.0%) Not reported Not reported
Monks et al. [15] 38/100 (38.0%) vs 42/97 (43.3%) 24/100 (26.0%) vs
26/97 (26.8%)
72/100 (72.0%) vs 77/97 (79.4%) 55/100 (55.0%) vs
38/97 (39.2%)
Hafez et al. [16] Not reported Not reported Not reported Not reported
Total 103/305 (33.8%) vs 119/309 (38.5%) 61/263 (23.2%) vs 77/262 (29.4%) 121/163 (74.2%) vs 131/162 (80.9%) 106/205 (51.7%) vs 82/206 (39.8%)
I [2] 30% 0% 9% 57%
RR (95% CI) 0.90 (0.69 to 1.17) 0.78 (0.58 to 1.04) 0.91 (0.81 to 1.03) 1.24 (0.90 to 1.69)
Data are reported as number in the intervention vs number in the control group.
RR, relative risk; CI, conﬁdence interval.
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Table 9
Neonatal Outcomes.
1 min APGAR
(median)
5 min APGAR
(median)
Umbilical cord
arterial pH
NICU admission Breast feeding
difﬁculties ﬁrst 24 hrs
Birth weight
(grams)
Positive Pressure
Ventilation
Moore et al. [11] 9 vs
9
9 vs 9 7.3  0.1 vs
7.3  0.1
1/21 (4.76%)
vs 0/23
(0)
3/20
(15%) vs
5/21
(23.81%)
3520  407 vs
3341  431
Not reported
Short et al. [12] 9 vs 9 9 vs 9 7.3  0.1
vs 7.3
 0.1
1/42 (2.4%)
2/42 (4.8%)
1/42 (2.4%) vs
7/42 (16.7%)
3505  431 vs
3382
553
2/42
(4.76%) vs
2/42
(4.76%)
Nofal et al. [13] 9 vs 9 9 vs 9 7.3  0.1 vs
7.3  0.1
2/42 vs
1/44
2/42 vs
1/44
3,251  522 vs
3,347  581
Not reported
Memari et al. [14] Not reported Not reported Not reported Not reported Not reported Not reported Not reported
Monks et al. [15] 9 vs 9 9 vs 9 7.3  0.1
vs 7.3  0.1
1/100 (1)
vs 4/97 (4.1)
16/91 (17.6) vs 17/88
(19.3)
3408  449.7 vs
3,347  5.5.5
3/100 (3)
vs 3/97 (3.1)
Hafez et al. [16] 9 vs 9 10 vs 10 Not reported Not reported Not reported Not reported Not reported
Total – – 7.3 vs 7.3 5/205 (2.4%) vs 7/
206 (3.4%)
22/195 (11.3%) vs 30/
195 (15/4%)
3407.2 vs 3353.5 5/142 (3.5%) vs
5/139 (3.6%)
I2 – – 22% 0% 20% 0% 0%
RR or MD (95% CI) – – 0.01 (0.02 to
0.00)
0.77 (0.23 to 2.62) 0.74 (0.37 to 1.48) 65.46 (30.73 to
161.66)
0.98 (0.29 to 3.31)
Data are reported as number in the intervention vs number in the control group.
MD, mean difference; CI, conﬁdence interval; RR, relative risk.
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assignments (Fig. 2).
All six trials included only healthy pregnant women with
singleton gestations undergoing cesarean delivery at term
under regional anesthesia. Healthy was deﬁned as ASA I or II,
which includes pregnant women with BMI less than 40 mg/kg,
with no medical problems or well controlled diabetes/
hypertension, or mild lung disease. There were a total of 320
women in the intervention group and 321 women in the
control group. VAS pain score was the most used primary
outcome, assessed in four of six trials and a total of 178 women
in the intervention group and 177 women in the control group
had available data for this outcome (Table 1). The mean
gestational age at randomization was about 38 weeks in both
groups (Table 2). All trials used 600 mg oral gabapentin as
intervention, and placebo as control, 1 h (in 5/6 trials) before
surgery and in one study gabapentin was continued postoper-
atively for 48 h (Table 3). Both gabapentin and placebo groups
received the same intrathecal opioids in each study (Table 3).
Only four trials reported on repeat cesarean (the majority of
women), and only two on type of skin incision (Pfannenstiel)
(Table 4). Immediate postoperative medications used in both
groups– an NSAID, usually ketorolac or diclofenac, as well as
acetaminophen - are reported in Table 5.
Synthesis of results
Women who received 600 mg oral gabapentin prior to cesarean
delivery, had lower VAS pain scores at 24 h postoperative on
movement compared to those who received placebo (36.4 vs 43.7,
MD -11.60, 95% CI-23.03 to -0.16; Fig. 3) (Table 6). VAS pain scores
at 6,12, 24, and 48 h at rest or after movement were not statistically
different for women receiving gabapentin and placebo although
there was a general trend towards lower VAS pain scores for
women receiving gabapentin (Table 6). There was no signiﬁcant
between-group difference in use of additional pain medications,
supplemental opioids, and persistent pain 6 weeks after cesarean
delivery (Table 7). There was a higher pain control satisfaction at 12
and 24 h in the gabapentin vs placebo groups (Table 7). There were
no signiﬁcant between-group differences in maternal side effects
of nausea, vomiting, pruritus, or sedation (Table 8). No data werereported in any study regarding headache, hypotension, and
shivering which were included in the initial study design. Neonatal
outcomes were similar in the two groups with respect to 1 and
5 min APGARs, birth weight, NICU admission, umbilical cord
arterial pH, breast feeding difﬁculties in ﬁrst 24 h, and need for
positive pressure ventilation (Table 9).
Discussion
In healthy term pregnant women undergoing cesarean delivery
under spinal anesthesia with intrathecal opioids, as well as
standing NSAIDs and acetaminophen postpartum, 600 mg oral
gabapentin 1 h before surgery was associated with lower VAS pain
scores in the postoperative period compared to those who received
placebo, reaching statistical signiﬁcance at 24 h on movement.
There is also a signiﬁcant difference in VAS pain score satisfaction
at 12 and 24 h although this ﬁnding is limited by having data from
only 2 and 3 studies respectively.
There is conﬂicting data regarding the efﬁcacy of perioperative
gabapentin to decrease postoperative pain. In non-pregnant
adults, some meta-analyses have failed to show an improvement
in postoperative pain scores or opioid use following perioperative
gabapentin administration while others have demonstrated
statistically signiﬁcant improvements in these outcomes when
perioperative gabapentin is used [17–21]. A meta-analysis by
Alayed et al showed decreasing postoperative opioid requirements,
as well as lower VAS pain scores in the ﬁrst 24 h following total
abdominal hysterectomy when 400 to 1800 mg gabapentin was
dosed perioperatively [7]. Importantly, this study included only
patients undergoing general anesthesia in contrast to our study,
which includes only patients receiving regional anesthesia with
intrathecal opioids where a postoperative analgesic effect is
expected for up to 36 h [5]. A meta-analysis by Doleman et al
included studies where patients received both general and spinal
anesthesia and showed a lesser effect on pain medication
requirements for patients that underwent spinal anesthesia
compared to general anesthesia when receiving preoperative
gabapentin [20]. In other words, preoperative gabapentin was
more effective in decreasing postoperative opioid consumption in
patients receiving general anesthesia compared to regional
anesthesia.
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conduct the analysis which followed criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions. All authors were
contacted directly and additional unpublished data was compiled for
analysis. Additionally, the included studies had low risk of bias.
This study is limited by characteristics inherent to the
individual studies included for analysis. Only four of the included
six studies assessed the primary outcome of VAS pain scores. Two
of four studies showed a decrease in postoperative VAS pain scores
and narcotic usage following pre-cesarean gabapentin adminis-
tration compared to placebo, while two showed no difference. Of
these four studies, three were adequately powered to detect such a
difference and one that failed to show an intervention effect was
not. Neuraxial medications and intraoperative/ postoperative
analgesic medications as well as dose and route varied between
studies but were overall similar. Women in all studies where
neuraxial medications are reported (5/6) received intrathecal
bupivacaine and fentanyl and in 3/5 studies women also received
intrathecal morphine. This study is also limited in generalizability
as all patients were healthy with ASA class I or II and patients with
substance use disorders or chronic pain syndromes were excluded.
Data regarding intraoperative surgical technique were not
reported and different techniques have been associated with
varying painfulness [2,22–24]. Original trials did not reported on
duration of surgery, or on abdominal adhesions.
An optimal approach to post partum pain control remains
incompletelycharacterized. Different approaches have been studied,
including antenatal and postnatal interventions [25–29]. Limiting
opioid usage in this period is a priority as data have shown that 1 in
300 opioid naïve individuals will continue to use opioids after the
postoperative period [6]. Current anesthesia guidelines recommend
a multi-modal, step-wise approach that is individualized to each
patient. Women receiving regional anesthesia with intrathecal
morphine should receive NSAIDs and acetaminophen with addi-
tional opioids reservedfor“severe breakthrough pain” [5]. Whilethis
meta-analysis is limited by a small number of patients, it does
support a role for prophylactic gabapentin in reducing postoperative
VAS pain scores after cesarean delivery. Importantly, no difference
was seen in maternal side effects or neonatal outcomes for patients
receiving preoperative gabapentin highlighting its safety for use in
this patient population.
Conclusions
In summary, prophylactic use of 600 mg oral gabapentin prior
to cesarean delivery improves postoperative pain control in
healthy patients (ASA I or II) undergoing spinal anesthesia with
intrathecal opioids, as well as receiving standing NSAIDs and
acetaminophen postpartum.
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